Stock data
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN) reported net income of -US$45.62M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | — | -US$45.62M | — |
| 2024 | — | — | — | -US$36.18M | — |
| 2023 | — | — | -US$43.00M | -US$116.54M | — |
| 2022 | — | — | -US$88.43M | -US$87.97M | — |
| 2021 | — | — | -US$36.87M | -US$34.51M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$31.63M | — |
| 2026-03-31 | — | -US$39.02M | — |
| 2025-12-31 | — | -US$10.45M | — |
| 2025-09-30 | — | -US$17.46M | — |
| 2025-06-30 | — | -US$11.22M | — |
| 2025-03-31 | — | -US$6.50M | — |
| 2024-12-31 | — | -US$44.62M | — |
| 2024-09-30 | — | US$76.97M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.